ARA-290
ARA-290 (cibinetide) is primarily being studied as a therapeutic peptide to treat chronic neuropathic pain associated with sarcoidosis and diabetic neuropathy, often targeting small fiber neuropathy (SFN). It operates by activating the innate repair receptor (IRR) to reduce inflammation, promote tissue repair, and provide pain relief without affecting red blood cell production
Key research areas for ARA-290 include:
- Small Fiber Neuropathy (SFN) and Sarcoidosis: Evaluated for reducing neuropathic symptoms, pain, and numbness in patients with sarcoidosis.
- Diabetic Neuropathy: Investigated for relieving pain and improving corneal nerve fiber density in diabetic patients.
- Diabetic Macular Edema (DMO): Studied as a potential treatment for vision improvement in diabetes patients.
- Inflammatory/Tissue Repair Conditions: Researched for its ability to reduce renal inflammation and protect against kidney injury.
(PubMed Central (PMC) (.gov)
Available studies linked below.
